EMERGENT BIOSOLUTIONS INC. Inventory, Raw Materials and Supplies, Net of Reserves
EMERGENT BIOSOLUTIONS INC. (EBS) had Inventory, Raw Materials and Supplies, Net of Reserves of $117.70 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves · last filed 2026-08-06
- 2026-06-30: Inventory, Raw Materials and Supplies, Net of Reserves $117.70M.
- 2026-03-31: Inventory, Raw Materials and Supplies, Net of Reserves $111.70M.
- 2025-12-31: Inventory, Raw Materials and Supplies, Net of Reserves $120.60M.
- 2025-09-30: Inventory, Raw Materials and Supplies, Net of Reserves $126.50M.
| Period end | Inventory, Raw Materials and Supplies, Net of Reserves | Inventory, Raw Materials and Supplies, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $117.70M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $111.70M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $120.60M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $126.50M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $108.90M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $93.80M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $95.90M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $86.70M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $97.20M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $130.50M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $128.70M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $142.30M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $140.30M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $148.90M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $142.30M 10-K · filed 2024-03-08 | $143.40M 10-K · filed 2023-03-01 |
| 2022-09-30 | $277.40M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $264.00M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $244.10M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $212.80M 10-K/A · filed 2023-12-11 | $217.50M 10-K · filed 2022-02-25 |
| 2021-09-30 | $198.80M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $174.30M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $194.30M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $160.60M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $116.80M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $81.70M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $77.70M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $70.50M 10-K · filed 2021-02-19 | |
| 2019-09-30 | $69.00M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $66.30M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $57.30M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $51.80M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $33.84M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $34.43M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $36.08M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $36.10M 10-K · filed 2019-02-22 | $36.07M 10-K · filed 2018-02-23 |
| 2017-09-30 | $34.08M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $33.62M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $33.26M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $30.69M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $31.24M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $27.88M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $25.71M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $21.27M 10-K · filed 2017-02-28 | $23.10M 10-K · filed 2016-02-29 |
| 2015-09-30 | $21.12M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $15.86M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $17.02M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $17.38M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $16.09M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $15.03M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $18.34M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $2.66M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $2.35M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $2.61M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $2.56M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $2.73M 10-K · filed 2014-03-10 | |
| 2011-12-31 | $2.31M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |